Hidroxicloroquina Basi (Hydroxychloroquine Sulfate)

Hydroxychloroquine, the active component of Hidroxicloroquina Basi, is employed in several therapeutic areas based on its antimalarial and immunomodulatory properties.

• Treatment and prophylaxis of malaria caused by susceptible Plasmodium species.
• Management of rheumatoid arthritis as a disease‑modifying antirheumatic drug (DMARD).
• Long‑term therapy for systemic lupus erythematosus to reduce disease activity.
• Adjunctive therapy in certain dermatologic conditions such as discoid lupus erythematosus.
• Use in certain cases of chronic inflammatory skin disorders such as cutaneous sarcoidosis.
• Investigational use in clinical trials for viral infections, though not approved for this indication.

• Hydroxychloroquine exerts its antimalarial effect by diffusing into the parasite’s digestive vacuole and raising the pH, which interferes with heme polymerization into hemozoin, leading to toxic heme accumulation. In autoimmune conditions, the drug accumulates in lysosomes of immune cells, inhibiting lysosomal activity and autophagy, and modulates antigen presentation and cytokine production, thereby dampening the abnormal immune response. It also affects Toll‑like receptor signaling pathways, contributing to its immunomodulatory profile.

Hydroxychloroquine may cause a range of adverse reactions, most of which are dose‑related and reversible after discontinuation, though monitoring is occasionally recommended.

Common

• Nausea, vomiting, or abdominal discomfort, often mild and transient.
• Diarrhea or loose stools that may occur early in therapy.
• Headache or dizziness, usually resolving without intervention.
• Skin rash or mild pruritus, typically limited to localized areas.

Serious

• Retinal toxicity that can cause visual field defects or loss of central vision, potentially irreversible if not detected early.
• Cardiac rhythm disturbances, including QT interval prolongation and rare cases of cardiomyopathy.
• Severe hypoglycemia, particularly in patients receiving insulin or oral hypoglycemic agents.

Before initiating Hidroxicloroquina Basi, clinicians should evaluate patient history and consider several precautionary measures to minimize risk.

• Assess baseline retinal function with ophthalmologic examination, especially for long‑term use.
• Review cardiac history and obtain ECG if risk factors for QT prolongation exist.
• Evaluate renal and hepatic function, adjusting therapy in severe impairment.
• Screen for glucose‑lowering medication use to avoid hypoglycemia.
• Counsel women of childbearing potential about unknown pregnancy safety and advise contraception.
• Monitor complete blood count periodically for hematologic abnormalities.
• Inform patients about the importance of reporting visual changes promptly.

Hydroxychloroquine can interact with other medicines, affecting its concentration or the safety profile of the co‑administered drug.

Avoid

• Concomitant use with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics) due to additive cardiac risk.
• Strong CYP3A4 inducers such as rifampin or carbamazepine, which may reduce hydroxychloroquine plasma levels.
• Concurrent use with high-dose chloroquine, which may increase risk of retinal toxicity.

Use with caution

• Antidiabetic drugs, because hydroxychloroquine may potentiate hypoglycemic effects.
• Digoxin, as hydroxychloroquine can increase serum digoxin concentrations.
• Cyclosporine or other immunosuppressants, requiring monitoring for enhanced immunosuppression.
• Anticoagulants such as warfarin, because hydroxychloroquine may alter INR values.